Concord Wealth Partners Agios Pharmaceuticals, Inc. Transaction History
Concord Wealth Partners
- $591 Million
- Q3 2024
A detailed history of Concord Wealth Partners transactions in Agios Pharmaceuticals, Inc. stock. As of the latest transaction made, Concord Wealth Partners holds 200 shares of AGIO stock, worth $8,392. This represents 0.0% of its overall portfolio holdings.
Number of Shares
200
Previous 200
-0.0%
Holding current value
$8,392
Previous $8,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding AGIO
# of Institutions
232Shares Held
58.1MCall Options Held
403KPut Options Held
469K-
Farallon Capital Management LLC San Francisco, CA5.66MShares$238 Million1.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.55MShares$233 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.86MShares$204 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V83.74MShares$157 Million2.8% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.83MShares$119 Million0.01% of portfolio
About AGIOS PHARMACEUTICALS, INC.
- Ticker AGIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,818,000
- Market Cap $2.3B
- Description
- Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...